Back
Results - Announcements
Ipca Laboratories Ltd consolidated sales up 16.73% on year in Q2FY2026, net profit surged by 36.65%
13-Aug-2026, 04:23
Ipca Laboratories Ltd share price ticked higher by 0.99% to Rs 1766.7 after the company's net profit saw a strong growth of 36.65% to Rs 422.81 crore, while revenue from operations gained 16.73% to Rs 2788.1 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.61%. It has improved by 0.97% over last one week and advanced by 11.17% in last one month while the market capitalization of Ipca Laboratories Ltd has inched up 1.92% and 10.02% in the same period respectively. Profit before tax (PBT) of Ipca Laboratories Ltd stood at Rs 572.08 crore in Q2 FY26, surging by 73.09% year-on-year, and jumping 41.45% quarter-on-quarter. EBITDA came in at Rs 644 crore, rallying 67.88% YoY and expanding by 65.14% sequentially. Total expenses rose by 10.82% to Rs 2229.4 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 638.14 crore, posting a minor increase of 7.68% YoY, while employee benefits expense was at Rs 601.56 crore, witnessing a strong rise of 12.86% YoY. For the TTM ended FY26, revenue from operations grew marginally by 7.91% to Rs 9646.33 crore, while net profit soared by 51.28% to Rs 1191.37 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 165264% to Rs 1804.11 crore, and PBT witnessed a strong rise of 39.02% to Rs 1572.52 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1141.97 crore in FY26, as against Rs 1321.32 crore in FY25. Ipca Laboratories Ltd rallied 28.37% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.
Ipca Laboratories Ltd share price ticked higher by 0.99% to Rs 1766.7 after the company's net profit saw a strong growth of 36.65% to Rs 422.81 crore, while revenue from operations gained 16.73% to Rs 2788.1 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, easing 4.61%. It has improved by 0.97% over last one week and advanced by 11.17% in last one month while the market capitalization of Ipca Laboratories Ltd has inched up 1.92% and 10.02% in the same period respectively. Profit before tax (PBT) of Ipca Laboratories Ltd stood at Rs 572.08 crore in Q2 FY26, surging by 73.09% year-on-year, and jumping 41.45% quarter-on-quarter. EBITDA came in at Rs 644 crore, rallying 67.88% YoY and expanding by 65.14% sequentially. Total expenses rose by 10.82% to Rs 2229.4 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 638.14 crore, posting a minor increase of 7.68% YoY, while employee benefits expense was at Rs 601.56 crore, witnessing a strong rise of 12.86% YoY. For the TTM ended FY26, revenue from operations grew marginally by 7.91% to Rs 9646.33 crore, while net profit soared by 51.28% to Rs 1191.37 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 165264% to Rs 1804.11 crore, and PBT witnessed a strong rise of 39.02% to Rs 1572.52 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 1141.97 crore in FY26, as against Rs 1321.32 crore in FY25. Ipca Laboratories Ltd rallied 28.37% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 2.83% during the same period.